Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.

Irene Y Cheung1, Arvind Sahota, Nai-Kong V Cheung

  • 1Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York.

Cancer
|October 16, 2004
PubMed
Summary

Monitoring peripheral blood (PB) for neuroblastoma (NB) tumor cells, in addition to bone marrow (BM) analysis, can provide valuable prognostic information. Patients with positive markers in both BM and PB face a higher risk of death.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the chimeric antigen receptor T cells and bispecific antibody duopoly: ex vivo armed T cells for solid tumors.

Frontiers in immunology·2026
Same author

Establishment of <sup>68</sup>Ga-DOTA-Based Pretargeted Radioimmunodiagnosis.

Molecular pharmaceutics·2026
Same author

Pretargeted <sup>177</sup>Lu/<sup>225</sup>Ac combination therapy of colorectal cancer.

Theranostics·2026
Same author

T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges.

Cell reports. Medicine·2026
Same author

Preclinical <sup>203/212</sup>Pb-DOTA-Based Pretargeted Radioimmunotherapy in Nude Mice Bearing Established Human Colorectal Cancer Xenografts.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

International journal of cancer·2026

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Pediatric Cancer Research

Background:

  • Bone marrow (BM) histology is the standard for detecting metastatic neuroblastoma (NB).
  • Circulating tumor cells in peripheral blood (PB) may offer additional prognostic insights beyond BM assessment.

Purpose of the Study:

  • To evaluate the utility of quantifying tumor cells in PB using GD2 synthase mRNA expression via qRT-PCR.
  • To correlate PB findings with BM analysis and standard disease detection methods in Stage 4 NB patients.

Main Methods:

  • Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to detect GD2 synthase mRNA in PB of 120 Stage 4 NB patients.
  • PB results were compared with simultaneous BM aspirate analysis and five standard diagnostic modalities.

Related Experiment Videos

Main Results:

  • GD2 synthase transcript was detected in 62 patients, with 13 showing PB positivity and negative BM.
  • Positive markers in either BM or PB correlated with higher relapse and death rates.
  • Patients with positive BM and PB (BM+PB+) had a significantly greater risk of death (P = 0.03) compared to BM+PB- patients.

Conclusions:

  • BM monitoring remains crucial for Stage 4 NB follow-up.
  • PB monitoring complements BM surveillance and provides informative data for patient management.